HC Wainwright Comments on TG Therapeutics Q1 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White expects that the biopharmaceutical company will post earnings of $0.28 per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS and Q4 2025 earnings at $0.42 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%.

TGTX has been the topic of several other research reports. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Up 0.2 %

TG Therapeutics stock opened at $35.19 on Thursday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business’s 50-day simple moving average is $30.92 and its two-hundred day simple moving average is $28.38. The company has a market cap of $5.48 billion, a PE ratio of -351.86 and a beta of 2.30. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $37.58.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after purchasing an additional 209,190 shares during the period. State Street Corp raised its holdings in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Soleus Capital Management L.P. raised its holdings in TG Therapeutics by 5.8% in the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after purchasing an additional 146,702 shares during the period. Clearbridge Investments LLC acquired a new position in TG Therapeutics in the 4th quarter worth about $55,237,000. Finally, Northern Trust Corp raised its holdings in TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after purchasing an additional 120,785 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.